Summary:
Ipca Laboratories shares jumped 11% after the company reported strong Q1 FY27 results, with revenue rising 21% and EBITDA growing 50% YoY. Net profit increased sharply, while EBITDA margin expanded to 24%. Management raised its FY27 revenue growth guidance to 14–16% and expects EBITDA margins of 23–24%. Strong earnings and improved guidance drove investor optimism, though FDA-related developments remain a key risk to watch.
Ipca Laboratories shares jumped 11% to ₹1,917 apiece on the BSE in intraday trade on Monday, August 17, after posting strong first-quarter results. The counter neared its 52-week high of ₹1,941.4 reached on July 17, 2026 and rose despite a broadly weak market. The stock climbed to ₹1,945.1 in intraday trade, before dropping to ₹1,843, or ₹108.80 higher, at 10:59 hours.
At 9:20 hrs, the pharma major’s shares were trading at ₹1,882.6 or 9% higher. The BSE Sensex was down 0.37% at the same time. About 81 lakh shares changed hands on the bourses in the first five minutes of the trading session, indicating strong demand.
Ipca Laboratories Q1FY27 Results
Ipca Laboratories reported a 21% year-over-year (YoY) rise in revenue to ₹2,788.1 crore for the January-March quarter of FY27. Its EBITDA jumped 50% YoY to ₹637.94 crore, while the EBITDA margin widened by 600 basis points to 24%. Net profit rose 72% YoY to ₹401.89 crore.
The Indian business grew 13% in the reported quarter. Branded formulations rose 16% and generics are up 8% in the same period. The company’s API business saw a 33% jump in exports and a 20% rise in the domestic market.
Meanwhile, the institutional export business more than doubled to ₹120 crore. Of this, ₹40 crore was due to carry-over supplies from March to April, which the company is not expecting to repeat. The management believes that this quarter’s results were driven by strong volumes, and the same momentum is unlikely to continue for the next fiscal year.
Check Out: Small-Cap Pharma Stocks
Upgraded FY27 Guidance
The management raised its FY27 revenue growth outlook to 14-16% from 12-13% after recording a strong first-quarter performance. Consolidated EBITDA is expected to be between 23% and 24%, compared to the previous guidance of 22%.
Revenues from the US are expected to rise by 15-17%. Unichem and Ipca together are launching 7-8 products. Unichem’s revenue growth outlook for FY27 remains unchanged at 10%, with an EBITDA margin of 13%. By FY29, the management expects consolidated EBITDA margin to reach 25-26%.
Why Did Ipca Labs Shares Surge?
The counter climbed after the release of the earnings due to increased profits and positive guidance on FY27. The EBITDA and PAT figures jumped significantly in Q1FY27, while revenue growth and margin expansion are expected to contribute to profit. These positives seem to have prompted investors to buy the stock despite the weak general market.
However, the market will be watching out for developments concerning FDA approvals and hope for more clarity on the situation, as it could impact the stock price in the near term.
Rolling 12-month price-to-earnings (P/E) ratio for Ipca Labs is 33.8x.
Check Out: List of Pharmacuetical Stocks on NSE/BSE
Financial Performance and Valuation
For the January-March quarter of FY27, the company posted a net profit of ₹422.8 crore, up 80.4% from ₹234.4 crore in the same period last year. Net sales jumped 20.8% to ₹2,788.1 crore from ₹2,308.9 crore.
In FY26, Ipca Laboratories’ net profit soared 51.3% year-over-year (YoY) to ₹1,191.4 crore from ₹787.5 crore. Its revenue grew 7.9% YoY to ₹9,551.7 crore.
